197/10,000 women-years for pregnant patients with a single prothrombotic mutation and 776/10,000 women-years Other special RMD situations. Factors other than diagnosis of SLE or presence of aPL may influence the choice of contraception in women with RMD. These include use of medications and presence or risk of osteoporosis. Immunosuppressive therapy does not preclude use of any contraceptive method, but there is concern that mycophenolate-containing medications may interfere with hormonal